Business · 05/04/1996Updated: 10/18/2026 · 1 min read
FDA Determines Regulatory Review Period for OPTIMMUNE Patent Extension
Summary
The Food and Drug Administration has officially confirmed the regulatory review period for OPTIMMUNE, a biopharmaceutical company, in accordance with federal regulations, following the submission of a patent extension application to the US Patent and Trademark Office.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →